Get the Stockscreener App
0.1249
9.49%
-0.0131
After Hours:
.13
0.0051
+4.08%
Omega Therapeutics Inc stock is traded at $0.1249, with a volume of 5.11M.
It is down -9.49% in the last 24 hours and down -85.88% over the past month.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
See More
Previous Close:
$0.138
Open:
$0.1334
24h Volume:
5.11M
Relative Volume:
6.00
Market Cap:
$6.92M
Revenue:
$3.10M
Net Income/Loss:
$-97.43M
P/E Ratio:
-0.0694
EPS:
-1.8
Net Cash Flow:
$-94.38M
1W Performance:
-73.17%
1M Performance:
-85.88%
6M Performance:
-92.41%
1Y Performance:
-96.61%
1-Day Range:
$0.1178
$0.1403
1-Week Range:
$0.1178
$0.54
52-Week Range:
$0.1178
$4.4599
Omega Therapeutics Inc Stock (OMGA) Company Profile
Name
Omega Therapeutics Inc
Sector
Industry
Phone
(617) 949-4360
Address
140 FIRST STREET, SUITE 501, CAMBRIDGE
Compare OMGA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMGA
Omega Therapeutics Inc
|
0.1249 | 6.92M | 3.10M | -97.43M | -94.38M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-18-24 | Initiated | Raymond James | Outperform |
| May-25-23 | Resumed | Jefferies | Buy |
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Sep-23-22 | Initiated | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Stock (OMGA) Latest News
It is Poised to be a Bull Market for Omega Therapeutics Inc (OMGA) - SETE News
A Guide To The Risks Of Investing In Omega Therapeutics Inc (OMGA) - Knox Daily
Flagship’s Omega Thera to file for bankruptcy - The Pharma Letter
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
OMGA’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle – market - HPBL
Flagship-backed Omega signals it’s headed toward bankruptcy - BioPharma Dive
How to interpret Omega Therapeutics Inc (OMGA)’s stock chart patterns - US Post News
Stock market today: Captivision surged by 113.56% whereas Volcon jumped by 88.61% in early trading - Business Upturn
Omega Therapeutics enters restructuring agreement - MSN
Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets - Marketscreener.com
Omega Therapeutics enters restructuring agreement By Investing.com - Investing.com Nigeria
Omega Therapeutics Initiates Restructuring Amid Financial Challenges - TipRanks
Omega Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Australia
Omega Therapeutics stock hits 52-week low at $0.44 - MSN
Omega Therapeutics announces board reshuffle and new director - MSN
Omega Therapeutics Announces Board Restructuring and Appointments - TipRanks
Omega Therapeutics, Inc. Announces Board Changes -January 28, 2025 at 04:28 pm EST - Marketscreener.com
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation – Company AnnouncementFT.com - Financial Times
Omega Therapeutics stock hits 52-week low at $0.52 - MSN
Omega Therapeutics stock hits 52-week low at $0.52 By Investing.com - Investing.com Canada
Omega Therapeutics faces loan default notice - Investing.com
Omega Therapeutics faces loan default notice By Investing.com - Investing.com UK
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Omega Therapeutics Announces Director Resignation - Investing.com
Omega Therapeutics Chair Resigns from Board of Directors - Defense World
Omega Therapeutics stock hits 52-week low at $0.74 - Investing.com India
Omega Therapeutics, Inc. Announces Resignation of Michelle C. Werner as Member of the Board of Directors and the Nominating and Corporate Governance Committee - Marketscreener.com
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Omega Therapeutics Faces Leadership Change and Takeover Proposal - Yahoo Finance
Omega Therapeutics stock hits 52-week low at $0.74 By Investing.com - Investing.com Canada
Omega Therapeutics Inc (NASDAQ: OMGA) Down -65.47% This Year: What Is Going To Happen Next - Stocks Register
Omega Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Omega Therapeutics announces board changes By Investing.com - Investing.com Nigeria
Omega Therapeutics announces board changes - Investing.com India
Omega Therapeutics Appoints New Director Ravi Mehrotra - TipRanks
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - Citeline News & Insights
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates - MSN
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Omega Therapeutics Inc Stock (OMGA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):